Literature DB >> 22608970

Disentangling early sensory information processing deficits in schizophrenia.

Anthony J Rissling1, David L Braff, Neal R Swerdlow, Gerhard Hellemann, Yuri Rassovsky, Joyce Sprock, Marlena Pela, Gregory A Light.   

Abstract

OBJECTIVE: The disentangling of early sensory information processing deficits and examination of their relationships to demographic and clinical factors are important steps for the validation of potential biomarkers and/or endophenotypes of schizophrenia. The aims of the present study were to characterize commonly used sensory event-related potential deficits, to determine whether they are (1) distinct from one another and (2) independently associated with important clinical characteristics.
METHODS: MMN, P3a and RON event-related potentials (ERP) were recorded from schizophrenia patients (SZ; n=429) and nonpsychiatric comparison subjects (NCS; n=286). Subgroup analyses on demographic and clinical variables were performed.
RESULTS: Schizophrenia patients exhibited robust ERP deficits at frontocentral electrodes (MMN: d=1.10; P3a: d=0.87; RON: d=0.77), consistent with previous studies. Each ERP component uniquely accounted for variance in amplitude and schizophrenia deficits. Amplitude reductions occurred with increasing age in both NCS and SZ patients. A small subset of patients prescribed combinations of 1st and 2nd generation antipsychotics exhibited significantly reduced MMN amplitude relative to other medication-defined subgroups.
CONCLUSIONS: MMN, P3a, and RON are dissociable deficits with distinct relationships to age and medication status in schizophrenia patients, potentially reflecting divergent pathophysiological processes. Reduced MMN in patients taking multiple antipsychotic medications appear to be attributable to greater severity of symptoms and functional impairments, rather than a medication effect. SIGNIFICANCE: Independent information processing deficits in schizophrenia patients may differentially contribute to the commonly observed deficits in neurocognitive and psychosocial functioning. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22608970      PMCID: PMC3436955          DOI: 10.1016/j.clinph.2012.02.079

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  42 in total

1.  Duration and frequency mismatch negativity in schizophrenia.

Authors:  P T Michie; T W Budd; J Todd; D Rock; H Wichmann; J Box; A V Jablensky
Journal:  Clin Neurophysiol       Date:  2000-06       Impact factor: 3.708

Review 2.  Involuntary attention and distractibility as evaluated with event-related brain potentials.

Authors:  C Escera; K Alho; E Schröger; I Winkler
Journal:  Audiol Neurootol       Date:  2000 May-Aug       Impact factor: 1.854

3.  Top-down control over involuntary attention switching in the auditory modality.

Authors:  E Sussman; I Winkler; E Schröger
Journal:  Psychon Bull Rev       Date:  2003-09

4.  P300 reduction and prolongation with illness duration in schizophrenia.

Authors:  D H Mathalon; J M Ford; M Rosenbloom; A Pfefferbaum
Journal:  Biol Psychiatry       Date:  2000-03-01       Impact factor: 13.382

5.  MMN and attention: competition for deviance detection.

Authors:  Elyse Sussman; István Winkler; Wenjung Wang
Journal:  Psychophysiology       Date:  2003-05       Impact factor: 4.016

6.  The effect of clozapine therapy on frontal lobe dysfunction in schizophrenia: neuropsychology and event-related potential measures.

Authors:  Ulrich Schall; Stanley V. Catts; Shail Chaturvedi; Barbara Liebert; Joanna Redenbach; Frini Karayanidis; Philip B. Ward
Journal:  Int J Neuropsychopharmacol       Date:  1998-07       Impact factor: 5.176

7.  Effects of risperidone on auditory event-related potentials in schizophrenia.

Authors:  Daniel Umbricht; Daniel Javitt; Gerald Novak; John Bates; Simcha Pollack; Jeffrey Lieberman; John Kane
Journal:  Int J Neuropsychopharmacol       Date:  1999-12       Impact factor: 5.176

8.  Preattentional and attentional cognitive deficits as targets for treating schizophrenia.

Authors:  David L Braff; Gregory A Light
Journal:  Psychopharmacology (Berl)       Date:  2004-04-30       Impact factor: 4.530

9.  Mismatch negativity in chronic schizophrenia and first-episode schizophrenia.

Authors:  Dean F Salisbury; Martha E Shenton; Carlye B Griggs; Aaron Bonner-Jackson; Robert W McCarley
Journal:  Arch Gen Psychiatry       Date:  2002-08

10.  Complex independent component analysis of frequency-domain electroencephalographic data.

Authors:  Jörn Anemüller; Terrence J Sejnowski; Scott Makeig
Journal:  Neural Netw       Date:  2003-11
View more
  33 in total

1.  Nonlinear dynamics underlying sensory processing dysfunction in schizophrenia.

Authors:  Claudia Lainscsek; Aaron L Sampson; Robert Kim; Michael L Thomas; Karen Man; Xenia Lainscsek; Neal R Swerdlow; David L Braff; Terrence J Sejnowski; Gregory A Light
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-11       Impact factor: 11.205

2.  Mismatch negativity is a breakthrough biomarker for understanding and treating psychotic disorders.

Authors:  Gregory A Light; Risto Näätänen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-30       Impact factor: 11.205

3.  Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis.

Authors:  Neal R Swerdlow; Savita Bhakta; Hsun-Hua Chou; Jo A Talledo; Bryan Balvaneda; Gregory A Light
Journal:  Neuropsychopharmacology       Date:  2015-06-11       Impact factor: 7.853

4.  Neurophysiological biomarkers informing the clinical neuroscience of schizophrenia: mismatch negativity and prepulse inhibition of startle.

Authors:  Gregory A Light; Neal R Swerdlow
Journal:  Curr Top Behav Neurosci       Date:  2014

5.  A longitudinal study of event related potentials and correlations with psychosocial functioning and clinical features in first episode psychosis patients.

Authors:  Caitlin K Monaghan; Sophie Brickman; Polly Huynh; Dost Öngür; Mei-Hua Hall
Journal:  Int J Psychophysiol       Date:  2019-05-17       Impact factor: 2.997

Review 6.  Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia.

Authors:  Gregory A Light; Neal R Swerdlow
Journal:  Ann N Y Acad Sci       Date:  2015-03-09       Impact factor: 5.691

7.  Meta-analysis of mismatch negativity to simple versus complex deviants in schizophrenia.

Authors:  Michael Avissar; Shanghong Xie; Blair Vail; Javier Lopez-Calderon; Yuanjia Wang; Daniel C Javitt
Journal:  Schizophr Res       Date:  2017-07-11       Impact factor: 4.939

8.  Rodent Mismatch Negativity/theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia.

Authors:  Migyung Lee; Andrea Balla; Henry Sershen; Pejman Sehatpour; Peter Lakatos; Daniel C Javitt
Journal:  Neuropsychopharmacology       Date:  2017-08-17       Impact factor: 7.853

9.  Using biomarkers to inform diagnosis, guide treatments and track response to interventions in psychotic illnesses.

Authors:  Veronica B Perez; Neal R Swerdlow; David L Braff; Risto Näätänen; Gregory A Light
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

10.  Demand and modality of directed attention modulate "pre-attentive" sensory processes in schizophrenia patients and nonpsychiatric controls.

Authors:  Anthony J Rissling; Sung-Hyouk Park; Jared W Young; Michelle B Rissling; Catherine A Sugar; Joyce Sprock; Daniel J Mathias; Marlena Pela; Richard F Sharp; David L Braff; Gregory A Light
Journal:  Schizophr Res       Date:  2013-03-11       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.